BRITISH MEDICAL JOURNAL VOLUME 290 26 JANUARY 1985 275
We thank the National Kidney Research Fund for their support
of this work.
References
1 Ellis HA, Peart KM. Azotaemic renal osteodystrophy-a quantitative study on
iliac bone. J Clin Pathol 1973;26:83-101.
2 Kanis JA. Features and pathophysiology of renal bone disease. In: Anderton
JL, Parsons FM, Jones DE, eds. Liting with renal failure. Lancaster: MTP
Press, 1978:159-82.
3 Moorhead JF, Tatler GLV, Baillod RA, Varghese Z, Wills MR, Farrow SC.
Effects of age, sex, and polycystic disease on progressive bone disease of renal
failure. Br Medj 1974;iv:557-60.
4 Palma FJM, Ellis HA, Cook DB, et al. Osteomalacia in patients with chronic
renal failure before dialysis or transplantation. Q J Med 1983;52:332-48.
5 Potter DE, Wilson CJ, Ozonoff MB. Hyperparathyroid bone disease in children
undergoing long-term hemodialysis: treatment with vitamin D. J Pediatr
1974;85 :60-6.
6 Broyer M. Chronic renal failure. In: Royer P, Habib R, Mathieu H, Broyer M,
eds. Pediatric nephrology. Philadelphia: W B Saunders, 1974:358-94.
7 Meema HE, Oreopoulos DG, Uldall PR. The influence of age and sex on bone
resorption of secondary hyperparathyroidism. Calcif Tissue Int 1984;36:25-30.
8 Pendras JP. Parathyroid disease in long-term maintenance hemodialysis. Arch
Intern Med 1969;124:312-21.
9 Kanis JA, Cundy T, Earnshaw M, et al. Treatment of renal bone disease with
le-hydroxylated derivatives of vitamin D,. Clinical, biochemical, radiographic
and histological responses. Q J Med 1979;48:289-322.
10 Kanis JA, Earnshaw M, Heynen G, et al. Changes in histologic and biochemical
indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin. N Engl J Med
1977;296: 1073-9.
11 Woods CG, Morgan DB, Patterson CR, Grossman HH. Measurement of osteoid
in bone biopsy. J Pathol Bacteriol 1968;95:441-7.
12 Fienberg SE. The analysis of cross-classified categorical data. Cambridge, Massachusetts: MIT Press, 1979.
13 Arnitage P. Statistical methods in medical research. Oxford: Blackwell, 1971.
14 Malluche HH, Ritz E, Kutschera J, Hodgson M, Seiffert U, Schreppe W.
Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:
355-62.
15 Ott SM, Maloney NA, Coburn JW, Alfrey AC, Sherrard DJ. The prevalence of
bone aluminium deposition in renal osteodystrophy and its relation to the
response of calcitriol therapy. N EnglJ Med 1982;307:709-13.
16 Bordier PJ, Marie PJ, Arnaud CD. Evolution of renal osteodystrophy: correlation
of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone levels before and after treatment with calcium carbonate or
25-hydroxycholecalciferol. Kidney Int 1975;7,suppl 2:S102-12.
17 Parfitt AM. Clinical and radiographic manifestations of renal osteodystrophy.
In: David DS, ed. Calcium metabolism in renal failure and nephrolithiasis.
New York: J Wiley, 1977:145-97.
18 Clark S. Longitudinal growth studies in normal and scoliotic children. In:
Zorab PA, ed. Scolions: proceedings of the 5th symposium. London: Academic
Press, 1977:165-80.
19 Nordin BEC. In: Nordin BEC, ed. Calcium, phosphate and magnesiwn metabolism.
Edinburgh: Churchill Livingstone, 1976:1-35.
20 Aksnes L, Akarsog D. Plaama concentrations of vitamin D metabolites in puberty:
effect of sexual maturation and implications for growth. j Clin Endocrinol
Metab 1982;55:94-101.
21 Mawer EB, Backhouse J, Taylor CM, Lumb GA, Stanbury SW. Failure of
formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency.
Lancet 1973;i:626-8.
22 Chesney RW, Moorthy AV, Eisman JA, Jax DK, Mazess RB, DeLuca HF.
Increased growth after long-term oral la,25-vitamin D, in childhood renal
osteodystrophy. N EnglJ Med 1978;298:238-42.
23 Mason RS, Lissner D, Wilkinson M, Poser S. Vitamin D metabolites and their
relationship to azotaemic osteodystrophy. Cln Endocrinol 1980;13:375-85.
24 Kurokawa K, Torikai S, Wang MS, Klein KL, Kawashima H. Metabolic
heterogeneity of the nephron. Mineral and Electrolyte Metabolism 1982;
7:225-36.
25 Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident
bone disease, nephrocalcinosis and nephrolithiasis in various types of renal
tubular acidosis. N EnglJ Med 1982;307:217-21.
26 Horsman A. Bone mass. In: Nordin BEC, ed. Calcim, phosphate and magnesium
metabolism. Edinburgh: Churchill Livingatone, 1976:357-404.
27 Mundy GR, Cove DH, Fisken R, Heath DA, Somers S. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1980;i:
1317-20.
28 Schalch DS, Gonzalez-Barcera D, Kastin AJ, et al. Plasma gonadotrophins after
administration of LH-releasing hormone in patients with renal or hepatic
failure. J Clin Endocrinol Metab 1975;41 :921-5.
29 Holdsworth S, Atkins RC, DeKretzer DM. The pituitary-testicular axis in men
with chronic renal failure. N EnglJ Med 1977;296:1245-9.
30 Eastwood JB, Bordier PJ, Clarkson EM, TunChot S, DeWardener HE. Vitamin
D deficiency in the osteomalacia of chronic renal failure. Lancet 1976;ii:
1209-11.
31 Cochran M, Bulusu L, Horsman A, Stasiak L, Nordin BEC. Hypocalcaemia and
bone disease in renal failure. Nephron 1973;10:113-40.
32 Cochran M, Nordin BEC. Role of acidosis in renal osteomalacia. Br Med J 1969;
ii:276-9.
33 Cundy T, Kanis JA, Heynen G, et al. Failure to heal vitamin D deficiency
rickets with conventional doses of 1,25-dihydroxyvitamin D,. Br Med J
1982;284:883-5.
34 Memmos DE, Eastwood JB, Talner LB, et al. Double blind trial of 1,25-
dihydroxyvitamin D, versus placebo in asymptomatic hyperparathyroidism
in patients receiving maintenance haemodialysis. Br MedJ7 1981;282:1919-24.
35 Nalk RB, Cundy T, Robinson BHB, Russell RGG, Kanis JA. Effects of vitamin D
metabolites and analogues on renal function. Nephron 1981;28:17-25.
36 Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I. Deterioration in renal function during treatment of chronic renal failure with 1,25-
dihydroxycholecalciferol. Lancet 1978;ii:700-3.
(Accepted 19 October 1984)
A prospective randomised controlled clinical trial
comparing somatostatin and vasopressin in controlling
acute variceal haemorrhage
S A JENKINS, J N BAXTER, W CORBETT, P DEVITT, J WARE, R SHIELDS
Abstract
Twenty two patients were entered into a randomised
controlied clinical trial comparing the efficacy of
somatostatin and vasopressin in controlling acute
variceal haemorrhage. Somatostatin was significantly
more successful in controlling acute variceal haemorrhage than vasopressin (p=0 003). Furthermore, no
complications were observed during treatment with
somatostatin.
University Department of Surgery, Royal Liverpool Hospital,
Liverpool L69 3BX
S A JENKINS, PHD, senior research assistant
J N BAXTER, MB, PRACS, lecturer
W CORBETT, MB, FRCS, lecturer
P DEVITT, MS, FRCS, lecturer
J WARE, mA, FRCS, senior lecturer
R SHIELDS, MD, FRcs, head of department and professor of surgery
Correspondence to: Professor R Shields.
Introduction
The main objective of vasoactive drug treatment of portal
hypertension is to control variceal haemorrhage until definitive
treatment can be undertaken. Although vasopressin has been
used for several years for the emergency control of bleeding
oesophageal varices,1 it is successful in only about half of all
patients.2 Moreover, treatment with vasopressin may have
undesirable side effects such as coronary vasoconstriction,
pulmonary oedema, and abdominal colic.3
Somatostatin, first isolated from the hypothalmus in 1972,4 is
widely distributed throughout the body, particularly high
concentrations being found in the central nervous system,
gastrointestinal tract, and pancreas. In addition to inhibiting
the release of many gastrointestinal hormones,5-7 somatostatin
is also a potent inhibitor of gastric and pancreatic secretions.8 9
Furthermore, studies of the effects of somatostatin on hepatic
haemodynamics in animals and on wedged hepatic venous
pressure in man have suggested that somatostatin may be
effective in controlling acute variceal haemorrhage."Â° '1 The
aim of this study was to compare the efficacy of somatostatin
and vasopressin in controlling acute variceal haemorrhage in a
prospective randomised controlled clinical trial.
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
.by guest on 6 October 2025 https://www.bmj.com/ Downloaded from 26 January 1985. 10.1136/bmj.290.6464.275 on Br Med J (Clin Res Ed): first published as 

276
Methods
We studied patients with appreciable variceal haemorrhage as
defined by: either systemic disturbance (pulse rate greater than
100 beats/minute, systolic blood pressure less than 100 mm Hg) for
two consecutive hours necessitating blood transfusion; or necessity
to transfuse two units of blood in 24 hours to maintain vital signs.
Bleeding varices were confirmed by endoscopy as the source of
haemorrhage in all patients.
Twenty two patients, satisfying the entry criteria, were randomly
allocated (using sealed envelopes) to receive intravenously either
vasopressin (argipressin; Ferring Pharmaceutical Company) or
somatostatin (Serono Laboratories, UK). The cause of portal
hypertension, grading of hepatic function according to Child's
criteria,12 age, sex, and ratio of index to interval episodes of bleeding
were similar in the two groups (table I). An index episode of bleeding
was defined as the first variceal haemorrhage and interval episodes
as all subsequent haemorrhages while the patient was undergoing
maintenance sclerotherapy.
TABLE i-Clinical features of patients with acute variceal haemorrhage recewirng
either vasopressin or somatostatin
Vasopressin Somatostatin
(n= 12) (n= 10)
No with portal hypertension due to:
Cirrhosis
Alcohol related 6 5
Cryptogenic 3 3
Primary biliary cirrhosis 1 0
Sarcoidosis 1 0
Paroxysmal nocturnal haemoglobinuria 0 1
Extrahepatic block 1 1
No with Child's classification:
A 2 2
B 4 2
C 6 6
Age (years):
Mean (SEM) 51-5 (2-9) 55 8 (5-0)
Range 30-73 39-72
No of men 6 6
No of episodes of bleeding:
Index 8 6
Interval 4 4
Patients selected to receive vasopressin were infused at a rate of
0-4 U/min for six hours. If bleeding stopped the rate of vasopressin
infusion was decreased to 0-2 U/min for the following six hours,
then decreased to 0-1 U/min for a further six hours, and finally
stopped if no further bleeding occurred. Patients allocated to receive
somatostatin received a bolus dose of 250 ,ug followed by a constant
infusion of 256 iLg/h for 24 hours. Twelve patients received vasopressin and 10 somatostatin. In 18 of the 22 patients vasopressin or
somatostatin was used as a first line treatment. In the four remaining
patients the varices had been injected on admission as an initial
treatment but, because of continued bleeding, they were randomised
to receive one or other drug (one vasopressin and three somatostatin).
Successful control of variceal haemorrhage was defined as the
stopping of bleeding as evidenced b-y the absence of fresh blood in
the nasogastric aspirate, stable packed cell volume, or absence of other
overt signs of continued bleeding during the 18-24 hours of administration of the vasoactive drug. If haemorrhage was not controlled
by the vasoactive drug balloon tamponade of the oesophagus was
undertaken using either a Minnesota or a Sengstaken Blakemore tube.
Results
SOMATOSTATIN
The variceal haemorrhage was successfully controlled in all 10
patients receiving somatostatin (fig 1). Seven of these patients were
subsequently treated with injection sclerotherapy (one to three days
later) without any further episodes of bleeding. The three others,
however, rebled before definitive treatment could be undertaken.
One of the patients who rebled had been randomised to receive
somatostatin after a massive haematemesis following emergency
sclerotherapy. The haemorrhage was successfully controlled by
infusion of somatostatin, but he rebled on two further occasions after
the infusion of somatostatin had been stopped. In both cases infusion
of somatostatin was again successful in controlling the variceal
bleeding. He subsequently underwent successful oesophageal tranBRITISH MEDICAL JOURNAL VOLUME 290 26 JANUARY 1985
section using a stapling technique. Another of the three to rebleed
refused injection sclerotherapy after initial control of her variceal
haemorrhage by somatostatin. She experienced four further appreciable episodes of bleeding in the three weeks after her initial
episode, all of which were controlled successfully by a 24 hour
infusion of somatostatin. She eventually died from multiple organ
failure. The third patient to rebleed did so after initial emergency
injection sclerotherapy for acute variceal haemorrhage. The bleeding
was successfully controlled by the administration of somatostatin,
but she subsequently sustained further massive variceal haemorrhage,
which was again controlled by somatostatin administration. She
underwent oesophageal transection under somatostatin cover but
subsequently died from a cardiac arrest in the intensive care unit. It
should be pointed out that she had had a cardiac arrest three hours
after admission with the initial episode of bleeding.
No complications were observed in any of the 10 patients during
infusion of somatostatin.
Somatostatin
(n-10)
Success Failure
(ns10) (n=O)
Sdlerotherapy Rebleed
(n=7) (n=3.7episodes)
Somantostatin
Success Failure
(n= 3) (n=O)
FIG 1-Outcome of treatment with
somatostatin in patients with acute variceal
haemorrhage.
VASOPRESSIN
Variceal haemorrhage was successfully controlled by vasopressin
in four of the 12 patients (one with Child's grade A hepatic function,
two with Child's grade B, and one with Child's grade C), but treatment was unsuccessful in the remaining eight (fig 2). In two patients
'*soRressin
(n-=12)
lnitial.Sue....s Failure
outcome (n-4) (n=8)
Sc&erotherapy Side effects Balloon tacinponade
(n=4) (n=2) and vasopressin
(n-=6)
Balloon tamponade Controlled Not controlled
I (n-4) (n=2)
Controlled Sclerotheupy Complications of
(n=2) balloon tamponode
(n=2)
FIG 2-Outcome of treatment with vasopressin in patients with acute
variceal haemorrhage.
administration of vasopressin had to be stopped despite continued
active bleeding from the varices because of undesirable side effects
(pulmonary oedema in one, chest pain and abdominal colic in the
other). Haemorrhage was eventually controlled in these two patients
by balloon tamponade.
Balloon tamponade was carried out in the six remaining patients
in whom vasopressin failed to control the variceal haemorrhage. In
four the variceal haemorrhage was eventually controlled by theProtected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
.by guest on 6 October 2025 https://www.bmj.com/ Downloaded from 26 January 1985. 10.1136/bmj.290.6464.275 on Br Med J (Clin Res Ed): first published as 

BRITISH MEDICAL JOURNAL VOLUME 290 26 JANUARY 1985
combination of balloon tamponade and vasopressin, but two of these
patients died from direct complications of balloon tamponade (inhalation in one case, oesophageal ulceration and perforation in the
other). In the two remaining patients the variceal haemorrhage was
not controlled by vasopressin and balloon tamponade. One of these
two underwent emergency oesophageal transection but died of liver
failure one week later. The other died of a combination of hypovolaemic shock and liver failure before any further treatment could
be undertaken.
COMPARISON
Analysis of the results by Fisher's exact test (table II) showed that
somatostatin was successful in a significantly greater number of
patients than vasopressin in controlling acute variceal haemorrhage
(p =0003). When the number of episodes of bleeding controlled by
somatostatin (17) was compared with the number controlled by
vasopressin (four) the difference between the treatments was of even
greater significance (p = 0-0002).
TABLE Ii-Results of vasopressin and somatostatin
treatment in controlling acute variceal haemorrhage.
Figures indicate numbers of patients in whom treatment
was successful or unsuccessful with numbers of episodes of
bleeding in parentheses
Successful Not successful
Vasopressin (n = 12) 4 8
Somatostatin (n = 10) 10 (17) 0
p = 0-003 (0-0002), Fisher's exact test.
Discussion
The results of this randomised controlled clinical trial suggest
that somatostatin is more successful than vasopressin in controlling acute variceal haemorrhage when success is defined as
the stopping of bleeding during the administration of the
vasoactive drug. Moreover, no complications were observed in
those patients who received somatostatin. Although we initially
intended to randomise 30 patients to receive either somatostatin
or vasopressin, an adverse report'3 prompted us to perform a
preliminary analysis of our data. The highly significant result
obtained (p=0 003) in the first 22 patients clearly indicated
that the trial should be stopped.
This paper describes the first full report of a randomised
clinical trial comparing the efficacy of somatostatin and vasopressin in controlling acute variceal haemorrhage. These
results agree with two previous reports, one of which is anecdotal,"1 the other reported in abstract form only.'4 Raptis and
Zoupas, however, in a study of only five patients found that
somatostatin had no beneficial effect in the control of acute
variceal haemorrhage.15 The reason for the difference in results
is difficult to explain. In our experience, success with the
administration of somatostatin demands scrupulous attention
to detail. The bolus injection must be given after the infusion
has been started, and there must be no delay in changing
infusion bags. Although Raptis and Zoupas gave a bolus
injection followed by a constant infusion for up to 74 hours,
they do not give any precise details of their methods of administration or any indication of the precautions they took to ensure
that the circulating concentrations of the hormone did not fall
to below that required to exert a therapeutic effect.'5 Furthermore, their failure to show a fall in portal pressure after administration of somatostatin at operation is contrary to observations in cirrhotic rats'6 and cirrhotic patients,'7 using roughly
the same dose of somatostatin. Their failure to show a beneficial
effect of somatostatin in the management of acute variceal
haemorrhage may have been related to the method of administration.
Somatostatin has been shown to reduce splanchnic blood
flow in experimental animals'6 "I and in man." On the basis of
277
these initial studies and the observation that somatostatin
lowers wedged hepatic venous pressure in patients with cirrhosis
the hormone was suggested to be of possible value in the
management of patients presenting with acute variceal haemorrhage."1 Reports on the effects of somatostatin on hepatic
haemodynamics in cirrhosis have, however, been contradictory.
Thus an infusion of somatostatin (1 jig/kg body weight/min)
has been reported to reduce wedged hepatic venous pressure in
man." Similarly, -Bosch et al observed that an injection (1 jtg/kg
body weight) or an infusion (7-5 ,ug/min) of somatostatin
significantly decreased both wedged hepatic venous pressure
and estimated liver blood flow in cirrhotic patients.'7 In contrast,
Sonnenberg et al reported that an infusion of somatostatin
250 jig/h had no effect on wedged hepatic venous pressure or
liver blood flow in cirrhotic patients."9 The rate of infusion of
somatostatin used by Sonnenberg et al (3-0 jxg/kg body weight/h)
was lower than that used in other clinical studies and roughly
midway between the rates of infusion of the hormone that either
have had no effect or have significantly lowered portal pressure
in cirrhotic rats." Furthermore, we have previously shown
that in cirrhotic rats the beneficial effects of an infusion of
somatostatin on hepatic haemodynamics are enhanced by
prior bolus administration of the hormone."1 It therefore seems
likely that the conflicting reports on the effects of somatostatin
on hepatic haemodynamics in cirrhotic patients may be related
to the amount given and the mode of administration.
The precise mode of action of somatostatin has not yet been
established. The rapidity of onset of its effects on hepatic
haemodynamics in experimental animals and in man suggests
that the peptide acts directly on the smooth muscle of the
splanchnic blood vessels."'
Although bleeding stopped during the infusion of somatostatin in all 10 patients, three of the patients rebled before
definitive treatment (either the first injection of sclerosant into
the varices or oesophageal transection) could be implemented.
These episodes of rebleeding were, however, controlled with
further infusions of somatostatin, suggesting that a more
prolonged infusion of the hormone may be necessary to reduce
further the risk of haemorrhage before definitive treatment is
carried out. Prolonged use of somatostatin alone may therefore
avoid the use of balloon tamponade with all its recognised risks
such as oesophagitis, rupture of oesophagus, aspiration pneumonia, and airway obstruction. The 25% mortality directly
attributable to balloon tamponade in this study is similar to
that previously reported.20
In addition, somatostatin has several other potential advantages over vasopressin in the management of bleeding oesophageal varices. Firstly, as somatostatin has been shown to
stop bleeding from peptic ulcer in about 80% of patients
presenting for treatment2l' the hormone will have the additional
benefit of controlling haemorrhage from other sources when
they coexist with oesophageal varices. Secondly, somatostatin
has been shown to be effective in controlling haemorrhage from
ulcerative oesophagitis, a condition that sometimes accompanies
bleeding oesophageal varices.22 Finally, somatostatin, by
inhibiting gastric acid secretion,8 may promote healing by
preventing clot dissolution.
In conclusion, somatostatin would appear to be more effective
than vasopressin in controlling acute variceal haemorrhage.
Furthermore, in both the present study and studies by other
workers2l administration of somatostatin has appeared to be
free from the complications observed during administration
of vasopressin. It therefore appears that somatostatin is an
effective stopgap measure, giving time for patients' conditions to
improve and diagnostic measures to be undertaken.
We thank Serono Laboratories UK Ltd for the gift of somatostatin
and for supporting the clinical trial; the junior medical and nursing
staff of the professional surgical unit, Royal Liverpool Hospital,
who helped with the care of the patients; and Mr K Tweedie and
Mr C West for statistical advice.
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
.by guest on 6 October 2025 https://www.bmj.com/ Downloaded from 26 January 1985. 10.1136/bmj.290.6464.275 on Br Med J (Clin Res Ed): first published as 

278 BRITISH MEDICAL JOURNAL VOLUmE 290 26 JANUARY 1985
ADDENDUM-Since this paper was accepted for publication a
report of a prospective randomised clinical trial comparing the
effects of somatostatin and vasopressin in the control of acute
variceal haemorrhage has been published (Kravetz D, Bosch J,
Teres J, Bruix J, Rimola A, Rodes J. Comparison of intravenous
somatostatin and vasopressin infusion in the treatment of
acute variceal haemorrhage. Hepatology 1984;4:442-6). There
was no difference in the effectiveness of somatostatin and
vasopressin in controlling variceal haemorrhage, but administration of somatostatin was associated with fewer complications.
The two trials are not, however, strictly comparable because
of differences, to which we have drawn attention (Hepatology,
in press), in the mode of administration of somatostatin and
vasopressin.
References
1 Kehne JH, Hughes FA, Gompertz ML. The use of pituitrin in the control of
esophageal varices: an experimental study and report of two cases. Surgery
1956;39:917-25.
2 Conn HO, Dalessio DJ. Multiple infusions of posterior pituitary extract in the
treatment of bleeding oesophageal varices. Ann Intern Med 1962;57:804-9.
3 Johnson WC, Widrich WC, Ansell JE, et al. Control of bleeding varices by vasopressin: a prospective randomised study. Ann Surg 1977;186:369-74.
4 Guillemin R. Hypothalmic peptide that inhibits the secretion of immunoreactive
pituitary growth hormone. Science 1973;179:77-9.
5 Wahren J, Felig P. Influence of somatostatin on carbohydrate disposal and
absorption in diabetes mellitus. Lancet 1976;ii:1213-6.
6 Bloom SiR. Somatostatin and the gut. Gastroenterology 1978;75:145-7.
7 Bloom SR, Mortimer Ch, Thomer MO, et al. Inhibition of gastrin and gastric
acid secretion by growth hormone release-inhibiting hormone. Lancet 1974;
ii:1106-9.
8 Gomez-Pan A, Reed JD, Albinus M, et al. Direct inhibition of gastric acid and
pepsin secretion by growth hormone release-inhibiting hormone in the cat.
Lancet 1975 ;i :888-90.
9 Raptis S, Schlegel W, Lehmann E, et al. Effects of somatostatin on the exocrine
pancreas and the release of duodenal hormones. Metabolism 1978;27(suppl 1):
1321-8.
10 Samnegard H, Thulin L, Andreen M, et al. Circulatory effects of somatostatin
on anaesthetised dogs. Acta Chir Scand 1979;145:209-12.
11 Tyden G, Samnegard H, Thulin L, et al. Treatment of bleeding oesophageal
varices with somatostatin. N Engl J Med 1978 ;29 :1466-7.
12 Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, Dunphy
JE, eds. Major problems in clinical surgery: the liver and portal hypertension.
Vol 1. Philadelphia: WB Saunders, 1964:1-85.
13 Anonymous. Bleeding oesophageal varices [Editorial]. Lancet 1984;i:139-41.
14 Basso N, Bagarani M, Quondamcarlo C, et al. Effective control of variceal
bleeding by somatostatin: a double-blind, randomized, cross-over study. Gastroeniterology 1983;84:100.
15 Raptis S, Zoupas C. Somatostatin not helpful in bleeding esophageal varices.
N Engl J Med 1979;300:736-7.
16 Jenkins SA, Devitt P, Shields R. The effect of somatostatin on hepatic haemodynamics in the cirrhotic rat. Langenbecks Arch Chir 1982;357:117-8.
17 Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic
haemodynamics in patients with cirrhosis of the liver and in normal subjects.
Gastroenterology 1981;80:526-32.
18 Konturek SJ, Tasler J, Cieszkowski M, et al. Effect of growth hormone release- inhibiting hormone on gastric secretion, mucosal blood flow, and serum
gastrin. Gastroenterology 1976;70:737-41.
19 Sonnenberg GE, Keller V, Ferruchoud A, et al. Effect of somatostatin on
splanchnic haemodynamics in patients with cirrhosis of the liver: comparison
with vasopressin. Gastroenterology 1981;80:518-25.
20 Parbhoo S. The management of bleeding in liver disease. Br J Hosp Med 1975;
15:17-28.
21 Kayasseh L, Gyr K, Keller V, et al. Somatostatin and cimetidine in peptic-ulcer
haemorrhage. Lancet 1980;i:844-6.
22 Bringer J, Dubois A, Richard JL, et al. Effets de la somatostatine dans les
hemorragies oesophagiennes. Une observation d'oesophagite ulcerce. Nosw
Presse Med 1980;17:1225-7.
23 Bosch J, Kravetz D, Terres J, et al. A controlled comparison of continuous
somatostatin and vasopressin in the treatment of acute variceal hacmorrhage.
Hepatology 1982;2:707.
(Accepted 23 October 1984)
Height at diagnosis of diabetes in children: a study in
identical twins
P J HOSKINS, R D G LESLIE, D A PYKE
Abstract
The height at diagnosis of 16 insulin dependent diabetics
aged under 19 was compared with that of their unaffected identical cotwins measured at the same time.
In eight pairs the diabetic was shorter, and in the remainder the cotwins were the same height. In those
dbetics who were shorter than their cotwins at diagnosis
the average period of growth delay before diagnosis was
at least 35 weeks; by contrast, the mean duration of
symptoms was only six weeks. No cause for the growth
delay other than the diabetes was known in any of the
twins.
These findings show that the onset of insulin dependent
diabetes may be a slow process, with delay
occurring several months before symptoms appear.
Diabetic Department, King's College Hospital, London SE5 9RS
P J HOSKINS, MRcP, MRC research fellow
R D G LESLIE, MD, MRCP, Wellcome Trust senior fellow and consultant
physician
D A PYKE, MD, FRcp, consultant physician
Correspondence and requests for reprints to: Dr D A Pyke.
Introduction
Growth is a sensitive indicator of health in childhood. Uncontrolled diabetes retards growth: before the discovery of
insulin growth stopped completely in children who developed
diabetes.' We have used these observations to determine
whether diabetes can be present, as shown by growth delay,
before the appearance of symptoms.
Studies of heights at diagnosis in diabetic children have
produced conflicting results. In most the diabetics were found
to be taller than expected,2-' although some studies showed
that their heights were normal8 10 1 or that they were shorter.12-"4
These discrepancies may be due to the difficulty in obtaining
exactly matched control groups. When comparing heights the
groups must be accurately matched for social class, racial
origin, and parental height. The ideal control for a diabetic
child is his unaffected identical twin, as twins usually grow at
the same rate and to the same final height.",
We studied the heights of identical twins discordant for
insulin dependent diabetes at the time of diagnosis of the
diabetic twin in order (a) to determine whether the diabetic
was taller or shorter at diagnosis than his unaffected cotwin
and (b), if there was a difference, to estimate how long before
diagnosis growth had been affected.
Subjects and methods
We studied identical twins included in the King's College Hospital
survey. Monozygosity was established as described."6
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. 
.by guest on 6 October 2025 https://www.bmj.com/ Downloaded from 26 January 1985. 10.1136/bmj.290.6464.275 on Br Med J (Clin Res Ed): first published as 

